

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

27 January 2026

**Ovoca Bio plc {to be renamed Talisman Metals PLC}**

("Talisman" or the "Company")

**Result of General Meeting  
Completion of Share Capital Reorganisation  
Issue of New Ordinary Shares  
Result of AGM**

Ovoca Bio plc (to be renamed Talisman Metals PLC) is pleased to provide the results of the General Meeting held earlier today in connection with the acquisition of Tadeen International Limited and other matters (the "Transaction"). All resolutions were passed and accordingly completion of the Acquisition will proceed along with issue of the New Ordinary Shares of €0.02 each (the "New Ordinary Shares"), the Consideration Shares and Fundraising Shares.

**Result of General Meeting**

At the General Meeting held today at 11am, all resolutions were passed on a show of hands.

A copy of the Notice of General Meeting, contained in the Admission Document, is available on the Company's website, <https://ovocabio.com>.

As previously announced on 31 December 2025, completion of the Acquisition and Admission of the Enlarged Share Capital to trading on AIM is expected to commence on 28 January 2026 at 8:00am. The ISIN for the New Ordinary Shares is IE000XRZAWV1 and SEDOL is BV5DLB8.

**Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Admission Document.**

**Result of AGM**

Furthermore, the Company has also held its AGM today and all resolutions proposed at the AGM were passed. A copy of the Notice of AGM is available on the Company's website.

Enquiries:

**Ovoca Bio plc**

Timothy McCutcheon, CEO

Tel: +353 (0) 1 525 6710

[info@ovocabio.com](mailto:info@ovocabio.com)

**Nominated Adviser**

Beaumont Cornish Limited

Tel: +44 (0) 20 7628 3396

Roland Cornish

James Biddle

**Broker**

CMC Markets UK plc

Tel: +44 (0) 20 3003 8255

Thomas Smith / Thomas Curran

**Financial PR**

BlytheRay PR

Tel: +44 (0) 20 7138 3204

Said Izagaren / James Mulligan / Matt Bowld

[talismanmetals@blytheray.com](mailto:talismanmetals@blytheray.com)

*Beaumont Cornish, which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively for the Company as Nomad in connection with the Admission and is not acting for any other person (including a recipient of this document) or otherwise be responsible to any person for providing the protections afforded to clients of Beaumont Cornish or for advising any other person in respect of the Admission or any transaction, matter or arrangement referred to in this document. The responsibility of Beaumont Cornish, as the Nomad, under the AIM Rules for Nominated Advisers is owed solely to the London Stock Exchange and is not owed to the Company or the Directors or any other person.*

*CMC Markets UK plc ("CMC") or (the "Broker"), which are authorised and regulated in the United Kingdom by the Financial Conduct Authority, are acting as sole broker to the Company in connection with the proposed re-admission of the Enlarged Share Capital to trading on AIM and the Admission. The Broker is acting exclusively for the Company and for no one else and will not be responsible to anyone other*

*on AIM and the Placing. The Broker is acting exclusively for the Company and for no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to the contents of this announcement or the Placing or the proposed re-admission of the Enlarged Share Capital to trading on AIM.*

*No representation or warranty, express or implied, is made by Beaumont Cornish, Broker or any of their respective Representatives as to the contents of this document (without limiting the statutory rights of any person to whom this document is issued). No liability whatsoever is accepted by Beaumont Cornish, Broker or any of their respective Representatives for the accuracy of any information or opinions contained in this document or for the omission of any material information for which it is not responsible. The information contained in this document is not intended to inform or be relied upon by any subsequent purchasers of Ordinary Shares (whether on or off exchange) and accordingly, to the extent permitted by law, no duty of care is accepted by the Company, Beaumont Cornish or Broker in relation to any of them.*

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMBRMITMTTTPF